Kuros Biosciences Competitors and Similar CompaniesClear all
Kuros Biosciences's competitors and similar companies include Merus, Olpha, Dermavant Sciences and Sorrento Therapeutics.
 Kuros Biosciences Kuros Biosciences is a biopharmaceutical company that engages in the development of biopharmaceutical products for tissue repair and bone regeneration. |  Merus Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. |  Olpha Olpha (formerly known as Olainfarm) is a company engaged in the development and manufacture of pharmaceutical products. |  Dermavant Sciences Dermavant Sciences, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics in medical dermatology. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
| |
Founding Date | Founding Date 2000 | Founding Date 2003 | Founding Date 1972 | Founding Date 2016 | Founding Date 2006 |
Type | Type Public | Type Public | Type Private | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Zürich, CH HQ Bilthoven, NL Boston, US | Locations Utrecht, NL HQ Cambridge, US | Locations Olaine, LV HQ | Locations Long Beach, US HQ Basel, CH Durham, US Morrisville, US New York, US Phoenix, US | Locations San Diego, US HQ San Diego, US |
Employees | Employees 122 | Employees 260 | Employees 2,191 | Employees 2228% decrease | Employees 31019% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 3.6 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 1.5 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $146.1m (FY, 2025) | Revenue (est.) $36.1m (FY, 2024) | Revenue (est.) €122.2m (FY, 2020) | Revenue (est.) N/A | Revenue (est.) $62.8m (FY, 2022) |
Cost of goods | Cost of goods $16.5m (FY, 2025) | Cost of goods N/A | Cost of goods €44.5m (FY, 2020) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $129.7m (FY, 2025) | Gross profit $36.1m (FY, 2024) | Gross profit €80.1m (FY, 2020) | Gross profit N/A | Gross profit N/A |
Net income | Net income $2.5m (FY, 2025) | Net income ($215.3m) (FY, 2024) | Net income €9.5m (FY, 2020) | Net income ($255.3m) (FY, 2019) | Net income ($577.8m) (FY, 2022) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 149.3m | Total funding raised N/A | Total funding raised $ 200m | Total funding raised $ 42.6m |
For sources of this data, please see the company profile
View Company Profiles
Merus
HQ
Utrecht, NL
Employees
260
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients.
View companyOlpha
HQ
Olaine, LV
Employees
2,191
Olpha (formerly known as Olainfarm) is a company engaged in the development and manufacture of pharmaceutical products.
View companyDermavant Sciences
HQ
Long Beach, US
Dermavant Sciences, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics in medical dermatology.
View companySorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View company